1H of FY2026

IR Materials

NIPRO CORPORATION
Board Director, CFO,
Senior Managing Officer
Takehito Yogo
November 10, 2026

Disclaimer

Forecasts and other forward-looking statements contained in this document are based on information currently available to the Company and on certain assumptions that the Company considers reasonable. Actual results may differ materially from those expressed or implied in these statements due to various factors , including fluctuations in foreign exchange rates, market conditions, competitive conditions, regulatory and approval developments, and other uncertainties.
Figures in tables may not add up to the totals due to rounding.

Information regarding NIPRO's medical devices, pharmaceutical products, and other products and services contained in this document is provided for informational purposes only and is not intended to solicit customers or provide medical advice.

Nothing in this document should be construed as a solicitation or recommendation to invest in the Company.
This document has been translated from the original Japanese version for reference purposes only. In the event of any discrepancy between the translated version and the original Japanese version, the original Japanese version shall prevail.

Table of Contents

1H FY2026 Results	– 4
1H FY2026 Operating Profit Bridge	– 5
Progress in FY2026	– 6
Approach to Achieving Full-Year Operating Profit Forecasts	– 7
Segment Sales & Operating Profit	– 8
Sales by Segment – 1H Results	– 9-11
Capex	– 12
Depreciation	– 13
Net Debt Reduction Plan for the Current Fiscal Year	– 14
–Appendix–	
Quarterly Results	– 16
Quarterly Sales and Operating Profit by Segment	– 17
Net Sales by Segment and Region	– 18
Net Sales by Segment and Product Category	– 19
Exchange rate / FX sensitivity / Product Classification Table	– 20

1H FY2026 Results

Unit : ¥100 million	1H FY2025	1H FY2026	Change (Change %)	Change Excl. FX Impact (Change %)
Net Sales	3,173.8	3,394.9	221.0	64.4
			+7.0%	+2.0%
Cost of sales (*1)	2,165.6	2,322.9	157.3	75.8
			+7.3%	+3.5%
Gross profit (*2)	1,008.1	1,071.9	63.7	-11.3
	31.8%	31.6%	+6.3%	-1.1%
SG&A expenses	854.8	926.8	72.0	27.3
	26.9%	27.3%	+8.4%	+3.2%
Operating profit	153.3	145.1	-8.2	-38.7
	4.8%	4.3%	-5.4%	-25.2%
Ordinary profit (*3)	82.3	54.9	-27.4	
	2.6%	1.6%	-33.3%	
Profit attributable to owners of parent	59.0	32.3	-26.6	
	1.9%	1.0%	-45.2%	

*1 A portion of manufacturing costs related to regenerative medicine has been reclassified to research and development expenses,with prior year figures adjusted accordingly.

*2 Effect of unrealized gains on gross profit
1H FY2025 +¥ 1,100 million
1H FY2026 - ¥ 240 million

*3 Foreign exchange losses
1H FY2025 - ¥ 1,300 million
1H FY2026 - ¥ 1,240 million

Net Sales

Medical-Related Segment :

Overseas – Sales growth in dialysis-related and vascular-related products, as well as the impact of the weaker yen. (YoY: ¥ 11.17 billion)

Domestic – Sales growth in hospital-related and dialysis-related products. (YoY: ¥ 5.17 billion)

Pharmaceutical-Related Segment :
Sales growth in injectable drugs and infusion products in own brands pharmaceuticals. (YoY: ¥ 3.70 billion)

PharmaPackaging Segment :
Sales growth driven by solid demand in Japan and a recovery in the U.S. market. (YoY: ¥ 3.26 billion)

Operating profit

Operating profit declined YoY due to a ¥15.73 billion increase in cost of sales and a ¥7.20 billion increase in SG&A expenses, mainly reflecting the consolidation of Gentuity and higher personnel and logistics costs.

Ordinary profit

Ordinary profit declined YoY, mainly due to a ¥1.66 billion increase in interest expenses.

Profit attributable to owners of parent

Although government subsidies of ¥1.27 billion were recorded, profit declined YoY due to the absence of the ¥4.14 billion gain on sale of property, plant and equipment recorded in the previous fiscal year.

1H FY2026 Operating Profit Bridge

Gentuity-related expenses and lower cost variance gains were offset by higher sales and favorable FX effects, resulting in operating profit in line with the initial forecast.

(¥100 million)



Progress in FY2026

1H: Revenue and operating profit were broadly in line with expectations, while ordinary profit and net profit fell short.
2H: Full-year targets are expected to be achieved through sales growth, improved profitability, and extraordinary gains.

Unit : ¥100 million	1H FY2026 Forecast	1H FY2026 Actual	1H FY2026 Forecast Achievement Rate	FY2026 Forecast	FY2026 Forecast Progress Rate
Net Sales	3,410.0	3,394.9	99.6%	7,000.0	48.5%
Cost of sales	2,270.0	2,322.9	102.3%	4,650.0	50.0%
Gross profit	1,140.0 33.4%	1,071.9 31.6%	94.0%	2,350.0 33.6%	45.6%
SG&A expenses	993.0 29.1%	926.8 27.3%	93.3%	1,950.0 27.9%	47.5%
Operating profit	147.0 4.3%	145.1 4.3%	98.7%	400.0 5.7%	36.3%
Ordinary profit	101.0 3.0%	54.9 1.6%	54.4%	274.0 3.9%	20.0%
Profit attributable to owners of parent	60.0 1.8%	32.3 1.0%	53.8%	150.0 2.1%	21.5%

Net Sales･Operating profit

1H: Results Within the Forecast Range
- Strong domestic medical and Own-brand pharmaceutical sales and the U.S. PharmaPackaging market recovery offset weaker demand ahead of the U.S. dialyzer transition and lower CDMO orders.

2H: On Track to Achieve Full-Year Forecast
- New U.S. dialyzer shipments and improved profitability in Hospital Products and CDMO to drive earnings growth.

Ordinary profit

1H: Results Below Forecast
- Impacted by ¥6.13billion in interest expense and ¥1.24billion in foreign exchange losses.

2H: On Track to Achieve Full-Year Forecast
- Expected to improve, primarily driven by higher operating profit.

Profit attributable to owners of parent

1H: Results Below Forecast
- Gain on the sale of fixed assets was deferred to 2H.

2H: On Track to Achieve Full-Year Forecast
- Expected to benefit from the gain on the sale of fixed assets deferred from 1H, as well as gains on the sale of investment securities.

Approach to Achieving Full-Year Operating Profit Forecasts


Key Elements


Segment		Details	Progress Status
Medical-Related	U.S.	Shipments of ELISIO™-HX Dialyzers Begin	3Q, 4Q
Pharmaceutical-Related	Own-Brand Pharmaceuticals	Launch of FORXIGA® AG DAPAGLIFLOZIN「NIPRO」	4Q
		Launch of Two GE Products	3Q, 4Q
	CDMO	Price Adjustments	1H, 3Q, 4Q
Medical-Related	Japan	Price Adjustments	1H, 3Q, 4Q

Segment Sales & Operating Profit

Profit decreased in the Medical-Related segment due to the consolidation impact of Gentuity. Additionally, profit in the Pharmaceutical-Related segment declined due to lower CDMO sales and higher labor and depreciation expenses. PharmaPackaging Segment profit increased on lower fixed costs and market recovery.

Unit : ￥100 million	Sales				Operating Profit		
	1H FY2025	1H FY2026	Change %	Change Excl. FX Impact (Change %)	1H FY2025	1H FY2026	Change %
Consolidated Total	3,173.8	3,394.9	+7.0%	+2.0%	153.3	145.1	-5.4%
Medical-Related segment	2,097.6	2,261.1	+7.8%	+1.5%	196.9	185.3	-5.9%
Pharmaceutical-Related segment	794.3	817.1	+2.9%	+2.5%	71.8	63.2	-11.9%
PharmaPackaging segment	272.3	305.0	+12.0%	+3.6%	-7.7	12.4	-
Corporate & Adjustments	9.4	11.5	+22.5%	-	-107.6	-115.9	-





Medical-Related Segment – 1H FY2026 Results

Segment Sales


¥226.1 billion

YoY : +7.8%
Ex-FX : +1.5%

Segment Profit

¥18.5 billion

YoY : -5.9%



China ¥20.0 billion
YoY : +12.6%
Ex-FX : -1.0%

Japan ¥74.8 billion
YoY : +6.9%
Ex-FX : -

Asia ¥24.2 billion
YoY : +18.9%
Ex-FX : +10.9%

Europe
¥47.8 billion
YoY : +9.1%
Ex-FX : -3.3%

Americas
¥59.1 billion
YoY : +2.5%
Ex-FX : -4.4%

※Ex-FX : Change Excluding Foreign Exchange Effects

■ Net sales :

Net sales increased as Japan and Asia drove real growth.

■ Operating profit :

Operating profit declined due to higher raw material and labor costs, as well as increased R&D expenses associated with the consolidation of Gentuity.

Region	Underlying Changes in Major Products(YoY)		Key Drivers of Changes (Excluding FX Impact)
Japan	↗ Dialysis	Dialyzers	Sales recovery, sales expansion initiatives.
	↗ Hospital	Needles	Stock-up demand due to the situation in the Middle East and the pass-through of higher costs.
	↗ Hospital	Other hospital-related products	(Saline Prefilled Syringes) Drug price increases due to the recalculation of unprofitable products.
Americas	↘ Dialysis	Dialyzers	Shipment Adjustments Ahead of the ELISIO-HX Transition.
	↗ Dialysis	Other dialysis-related products	(Dialysis center) Increase in the number of patients and demand for dialysis treatment in Latin America.
	↗ Dialysis	Dialysis solution	Winning tenders in Latin America.
Europe	↘ Dialysis	Dialyzers	Price competition and reduced orders/project delays due to the situation in the Middle East
	↗ Vascular		Strong sales performance.
Asia	↗ Vascular		Strong sales performance.
	↗ Hospital	Needles	Winning tenders, expanding production capacity.
	↗ Dialysis	Dialysis Machines	Strong sales performance.
China	↘ Dialysis	Dialysis Machines	Impact of policies favoring domestic products.
	↘ Vascular		Consumers held off on purchases because the start of centralized procurement was imminent.
	↗ Dialysis	Dialyzers	Centralized procurement, price increase, sales volume increase.

Pharmaceutical-Related Segment – 1H FY2026 Results

Segment Sales

¥81.7 billion

YoY : +2.9%

Ex-FX : +2.5%

Segment Profit

¥6.3 billion


YoY : -11.9 %

■ Net sales :

Higher Net sales of injectable drugs under our own brands offset lower orders for originator and long-listed products in the CDMO business.

■ Operating profit :

Operating profit declined due to lower sales in the CDMO business and higher labor costs, among other factors.



※Ex-FX : Change Excluding Foreign Exchange Effects

Distinction		Underlying Changes in Major Products(YoY)		Key Drivers of Changes (Excluding FX Impact)
Own-Brand Pharmaceuticals	Generic drugs ・Others	↗	Injectable drugs	Higher sales of BS products, anticancer drugs, and antibacterial drugs.
		↗	Oral drugs	Higher sales of new products.
		↘	Other	(External use drugs) Lower sales due to the impact of discontinued products.
CDMO	Generic drugs	↗	Oral drugs	Higher orders (Increase in new co-developed products)
		↘	Injectable drugs	Timing shifts in orders for some contracted products. Anticancer drugs are currently performing well.
	Brand-name / Long-listed drugs	↘	Injectable drugs	Decrease in orders (including lower volumes due to the phase-out of contract manufacturing)
		↘	Oral drugs	Decrease in orders (including the discontinuation of unprofitable contract-manufactured products)
	Other drugs	↗	Other	Higher sales from trial production prior to commercial production.

PharmaPackaging Segment – 1H FY2026 Results

Segment Sales


¥30.5 billion

YoY : +12.0%
Ex-FX : +3.6%

Segment Profit

¥1.2 billion

YoY : -



Asia ¥1.9 billion
YoY : +25.4%
Ex-FX : +16.5%

Japan ¥8.5 billion
YoY : +11.7%
Ex-FX : -

America ¥6.4 billion
YoY : +22.3%
Ex-FX : +13.7%

Europe ¥13.5 billion
YoY : +6.3%
Ex-FX : -6.9%

※Ex-FX : Change Excluding Foreign Exchange Effects

■ Net sales :

Net sales increased, driven by solid demand in Japan and market recovery in the Americas.

■ Operating profit :

Operating profit increased, driven by higher sales of high value-added products and lower labor costs resulting from workforce reductions in India, the U.S. and Europe.

Distinction	Underlying Changes in Major Products(YoY)		Key Drivers of Changes (Excluding FX Impact)
Japan	↗	Other PharmaPackaging products (Kit products etc.)	Increased demand for local anesthetics for dental use.
Europe	↘	Glass syringes	Timing shifts in shipments.
America	↗	Glass vials	Market recovery.
	↗	Glass tubing-related products	Higher demand for high value-added products for biopharmaceuticals.
Asia (※1)	↗	Glass ampoules	Strong sales of processed products to key customers, particularly ampoules.

(※1) Previously, we disclosed “China” and “India” separately. From FY2026, these regions are combined and disclosed as “Asia.”

Capex

Continued investment in ongoing projects and maintenance and upgrades, primarily in Medical-Related Segment. New investments in low-return businesses remain frozen.

Unit : ¥100 million	1H FY2025	1H FY2026	Change
Capex	243.1	253.0	+9.9
Medical-Related	153.0	162.1	+9.1
Pharmaceutical-Related	52.0	47.8	-4.2
PharmaPackaging	28.6	34.0	+5.3
Corporate & Adjustments	9.3	8.9	-0.3

*Capital expenditures include investments in tangible fixed assets only.

Medical-Related Segment

〈Key Capital Investments in 1H FY2026〉

- ✓ Dialyzer capacity expansion at the Vietnam Plant. (ongoing projects)
- ✓ Construction of the new U.S. Plant. (ongoing projects)
- ✓ Land acquisition for relocation of the dialysis solution plant in Spain. (ongoing projects)

Pharmaceutical-Related Segment

〈Key Capital Investments in 1H FY2026〉

- ✓ Vial Building at Nipro Pharma Omi Plant. (ongoing projects)

PharmaPackaging Segment

〈Key Capital Investments in 1H FY2026〉

- ✓ High-value-added syringe production line for the German plant. (ongoing projects)

Depreciation


Depreciation expenses decreased by ¥0.7 billion YoY, partly due to the adoption of the straight-line depreciation method for domestic group companies beginning in FY2026.

Unit : ¥100 million	1H FY2025	1H FY2026	Change
Depreciation Total	301.5	294.2	-7.2
Medical-Related	166.5	160.8	-5.6
Pharmaceutical-Related	72.9	72.2	-0.6
PharmaPackaging	34.4	34.7	+0.2
Corporate & Adjustments	27.6	26.5	-1.0

Net Debt Reduction Plan for the Current Fiscal Year

In addition to generating operating cash flow, we will strengthen our financial position through asset sales and other measures, targeting net debt of ¥500 billion or below by the end of FY2026.

Unit: ¥100 million



※CB conversion: Conversion into shares through the exercise of stock acquisition rights attached to convertible bonds with stock acquisition rights (Convertible Bonds).

Appendix

Quarterly Results

Unit : ¥100 million	1Q FY2025	2Q FY2025	3Q FY2025	4Q FY2025	1Q FY2026	2Q FY2026	FY2026 Forecast
Net Sales	1,592.2	1,581.6	1,699.2	1,732.3	1,675.4	1,719.4	7,000.0
Cost of sales	1,087.1	1,078.4	1,183.9	1,159.0	1,135.7	1,187.2	4,650.0
Gross profit	505.0	503.1	515.3	573.2	539.7	532.2	2,350.0
	31.7%	31.8%	30.3%	33.1%	32.2%	31.0%	33.6%
SG&A expenses	432.9	421.8	401.2	464.5	462.6	464.1	1,950.0
	27.2%	26.7%	23.6%	26.8%	27.6%	27.0%	27.9%
Operating profit	72.1	81.2	114.0	108.7	77.1	68.0	400.0
	4.5%	5.1%	6.7%	6.3%	4.6%	4.0%	5.7%
Ordinary profit	35.1	47.1	93.7	21.1	66.0	-11.1	274.0
	2.2%	3.0%	5.5%	1.2%	3.9%	-0.6%	3.9%
Profit attributable to owners of parent	32.7	26.3	107.7	-31.7	38.3	-6.0	150.0
	2.1%	1.7%	6.3%	-1.8%	2.3%	-0.3%	2.1%

Quarterly Sales and Operating Profit by Segment

Unit : ¥100 million	1Q FY2025	2Q FY2025	3Q FY2025	4Q FY2025	1Q FY2026	2Q FY2026	FY2026 Forecast
Consolidated Total	1,592.2	1,581.6	1,699.2	1,732.3	1,675.4	1,719.4	7,000.0
Medical-Related segment	1,054.3	1,043.2	1,103.0	1,162.0	1,119.3	1,141.7	4,691.0
Pharmaceutical-Related segment	399.6	394.6	466.6	412.7	406.8	410.3	1,697.0
PharmaPackaging segment	134.1	138.2	122.3	152.3	144.1	160.8	582.0
Corporate & Adjustments	3.9	5.4	7.1	5.2	5.0	6.5	30.0

Unit : ¥100 million	1Q FY2025	2Q FY2025	3Q FY2025	4Q FY2025	1Q FY2026	2Q FY2026	FY2026 Forecast
Consolidated Total	72.1	81.2	114.0	108.7	77.1	68.0	400.0
Medical-Related segment	103.1	93.7	103.1	144.0	98.5	86.8	445.0
Pharmaceutical-Related segment	40.1	31.7	54.2	27.6	37.3	25.8	146.0
PharmaPackaging segment	1.4	-9.1	-2.6	-4.6	1.4	11.0	16.0
Corporate & Adjustments	-72.6	-35.0	-40.7	-58.1	-60.1	-55.7	-207.0

Net Sales by Segment and Region *Based on destination

Region	Segment Unit : ¥100 million	Medical -Related	Pharmaceutical -Related	Pharma Packaging	Corporate & Adjustments	Total
Japan	**1H FY2026**	**755.3**	**768.5**	**85.2**	**11.3**	**1,620.4**
	1H FY2025	703.6	754.8	76.4	8.6	1,543.5
Overseas Total	**1H FY2026**	**1,505.7**	**48.6**	**219.7**	**0.2**	**1,774.4**
	1H FY2025	1,393.9	39.5	195.9	0.8	1,630.3
Americas	**1H FY2026**	**597.3**	**-**	**58.0**	**0.0**	**655.4**
	1H FY2025	590.1	-	49.7	0.1	640.0
Europe	**1H FY2026**	**388.2**	**1.2**	**136.9**	**0.0**	**526.4**
	1H FY2025	348.3	2.1	129.3	-	479.8
China	**1H FY2026**	**202.9**	**0.1**	**13.8**	**0.0**	**216.9**
	1H FY2025	179.4	0.1	9.4	0.2	189.2
Asia	**1H FY2026**	**317.2**	**47.2**	**10.8**	**0.1**	**375.5**
	1H FY2025	276.1	37.2	7.4	0.4	321.2
Consolidated Total	**1H FY2026**	**2,261.1**	**817.1**	**305.0**	**11.5**	**3,394.9**
	1H FY2025	2,097.6	794.3	272.3	9.4	3,173.8

Net Sales by Segment and Product Category *Based on destination

		Overall				Overseas				Japan			
	Unit : ¥100 million	1H FY2025	1H FY2026	Change	Change %	1H FY2025	1H FY2026	Change	Change %	1H FY2025	1H FY2026	Change	Change %
Medical-Related Segment	Dialyzers	548.5	577.9	+29.4	+5.4%	440.6	460.7	+20.1	+4.6%	107.8	117.1	+9.2	+8.6%
	Dialysis machine	146.9	153.0	+6.0	+4.1%	117.7	124.4	+6.6	+5.7%	29.2	28.6	-0.6	-2.1%
	Other dialysis-related products	444.6	508.7	+64.0	+14.4%	365.0	426.3	+61.3	+16.8%	79.6	82.3	+2.7	+3.4%
	Dialysis-Related Products Total	**1,140.1**	**1,239.7**	**+99.6**	**+8.7%**	**923.3**	**1,011.5**	**+88.2**	**+9.6%**	**216.7**	**228.1**	**+11.3**	**+5.3%**
	Needles	304.5	341.3	+36.8	+12.1%	211.1	230.3	+19.1	+9.1%	93.3	111.0	+17.6	+18.9%
	Infusion-related products	112.9	122.5	+9.5	+8.5%	50.6	55.1	+4.5	+9.0%	62.3	67.3	+5.0	+8.0%
	Diabetes-related products	60.2	60.2	+0.0	-0.1%	53.6	48.0	-5.5	-10.3%	6.6	12.1	+5.4	+81.7%
	Other hospital-related products	304.9	307.1	+2.1	+0.7%	105.9	96.6	-9.2	-8.8%	199.0	210.4	+11.4	+5.8%
	Hospital-Related Products Total	**782.8**	**831.2**	**+48.4**	**+6.2%**	**421.3**	**430.2**	**+8.8**	**+2.1%**	**361.4**	**401.0**	**+39.6**	**+11.0%**
	Vascular products	**174.6**	**190.0**	**+15.4**	**+8.8%**	**49.2**	**63.9**	**+14.7**	**+29.9%**	**125.4**	**126.1**	**+0.6**	**+0.5%**
	Medical Segment Total	**2,097.6**	**2,261.1**	**+163.4**	**+7.8%**	**1,393.9**	**1,505.7**	**+111.7**	**+8.0%**	**703.6**	**755.3**	**+51.7**	**+7.3%**
Pharmaceutical-Related Segment	Oral drugs	260.9	262.8	+1.9	+0.7%	36.3	44.5	+8.2	+22.7%	224.5	218.2	-6.3	-2.8%
	Injectable drugs and infusion products	155.1	189.0	+33.9	+21.9%	0.3	0.6	+0.2	+66.7%	154.7	188.4	+33.6	+21.8%
	Other drugs	46.9	48.1	+1.2	+2.6%	0.2	-	-0.2	-100.0%	46.7	48.1	+1.4	+3.1%
	Own-Brand Pharmaceuticals Total	**463.0**	**500.0**	**+37.0**	**+8.0%**	**36.9**	**45.2**	**+8.2**	**+22.4%**	**426.0**	**454.8**	**+28.7**	**+6.8%**
	Oral drugs	130.8	134.4	+3.5	+2.7%	0.2	0.1	+0.0	-25.9%	130.6	134.2	+3.6	+2.8%
	Injectable drugs and infusion products	178.7	154.5	-24.1	-13.5%	1.6	1.2	-0.4	-27.3%	177.0	153.3	-23.7	-13.4%
	Other Dosage Forms	21.8	28.1	+6.3	+29.0%	0.6	2.0	+1.3	+191.6%	21.1	26.1	+4.9	+23.6%
	CDMO Total	**331.3**	**317.0**	**-14.2**	**-4.3%**	**2.5**	**3.3**	**+0.8**	**+31.3%**	**328.7**	**313.6**	**-15.0**	**-4.6%**
	Pharmaceuticals Segment Total	**794.3**	**817.1**	**+22.7**	**+2.9%**	**39.5**	**48.6**	**+9.0**	**+23.0%**	**754.8**	**768.5**	**+13.7**	**+1.8%**
PharmaPackaging Segment	Glass tubing-related products	62.7	69.8	+7.0	+11.2%	49.2	55.8	+6.5	+13.4%	13.5	14.0	+0.4	+3.5%
	Glass ampoules	39.1	47.3	+8.1	+20.8%	39.0	47.2	+8.1	+20.9%	0.0	0.0	+0.0	-15.9%
	Glass vials	61.1	69.2	+8.1	+13.3%	50.8	57.9	+7.0	+13.9%	10.3	11.3	+1.0	+10.2%
	Glass syringes	39.8	35.6	-4.2	-10.7%	39.6	35.4	-4.1	-10.6%	0.1	0.1	+0.0	-31.9%
	Other products	69.4	83.0	+13.6	+19.6%	17.0	23.2	+6.2	+36.3%	52.3	59.7	+7.4	+14.1%
	PharmaPackaging Segment Total	**272.3**	**305.0**	**+32.6**	**+12.0%**	**195.9**	**219.7**	**+23.8**	**+12.2%**	**76.4**	**85.2**	**+8.8**	**+11.6%**
Corporate & Adjustments	Sales of production machinery and real estate leasing	**4.9**	**5.1**	**+0.1**	**+3.5%**	**0.1**	**0.0**	**+0.0**	**-79.5%**	**4.8**	**5.1**	**+0.2**	**+5.5%**
	Regenerative medicine products	**3.6**	**5.8**	**+2.2**	**+61.1%**	**-**	**-**	**-**	**-**	**3.6**	**5.8**	**+2.2**	**+61.1%**
	Corporate & Adjustments Total	**9.4**	**11.5**	**+2.1**	**+22.5%**	**0.8**	**0.2**	**-0.5**	**-66.2%**	**8.6**	**11.3**	**+2.6**	**+30.9%**
	Consolidated Total	**3,173.8**	**3,394.9**	**+221.0**	**+7.0%**	**1,630.3**	**1,774.4**	**+144.1**	**+8.8%**	**1,543.5**	**1,620.4**	**+76.9**	**+5.0%**

Exchange rate / FX sensitivity / Product Classification Table

<Average rate>

	FY2025				FY2026				
	Jan-Mar	Jan-Jun	Jan-Sep	Jan-Dec	Jan-Mar	Jan-Jun	Jan-Sep	Jan-Dec	Forecast
¥/USD	151.21	147.48	147.78	149.78	156.45	158.59	-	-	143.00
¥/EUR	159.35	162.24	165.57	169.53	183.53	184.83	-	-	169.00
¥/CNY	20.75	20.34	20.48	20.87	22.64	23.13	-	-	20.00

<Closing rate>

	FY2025	FY2026
	As of Sep 30	As of Sep 30
¥/USD	148.88	157.35
¥/EUR	174.47	178.34
¥/CNY	20.88	23.45

<FX Sensitivity>
*Per ¥1 Depreciation

Unit : ¥100 million

	Net Sales	Operating Profit
¥/USD	+10.2	-0.1
¥/EUR	+6.3	+1.9
¥/CNY	+18.4	+7.6

<Product Category>

Category		Product Group	Key Products
Medical-Related Segment	Dialysis-related products	Dialyzers	Dialyzers (artificial kidneys), HDF filters
		Dialysis machine	Dialysis systems, maintenance, dialysis machine parts
		Other dialysis-related products	Blood circuits, AVF needles (Winged IV Catheters), Powdered Dialysate, Dialysis fluids, etc.
	Hospital-related products	Needles	PSV needles(Winged IV Catheters), Safetouch needles, etc.
		Infusion-related products	Infusion sets, IV cannulas, etc.
		Diabetes-related products	Insulin needles, Blood glucose meters (for overseas markets), lancets
		Other hospital-related products	Gloves、Mechanical circulatory support, Cardiopulmonary bypass products、Neo tube, etc.
	Vascular -related products	Vascular products	Catheter sets for cardiovascular treatments, Thrombus aspiration catheters, etc.
Pharmaceutical-Related Segment	Own brands pharmaceutical products /CDMO	Oral drugs	Oral drugs
		Injectable drugs and infusion products	Syringe kits, Vial formulations, Dual chamber bags (PLW) , etc.
		Other drugs	External use drugs, patches、Diagnostic Reagents, etc.
PharmaPackaging Segment	PharmaPackaging products	Glass tubing-related products	Medical-use glass tubing, Non-medical use glass tubing
		Glass ampoules	Ampoules (Single tip, Double tip)
		Glass vials	Vials (Blowback, Screw, etc.)
		Glass syringes	Syringes〈Luer lock, Luer slip, Sterilized, etc.)
		Other PharmaPackaging products	Rubber stoppers, Plastics, Cartridge glass and others, etc.
Corporate & Adjustments		Regenerative Medicine	
		Machinery Sales and Real Estate Leasing	


NIPRO
Live Longer. Live Better.